Answers are grounded in this paper and cite their sources.
Preclinical study reveals netrin-1 limits CCL2-driven macrophage migration and prevents aortic sinus enlargement in hyperlipidaemic mice, suggesting a therapeutic role against vascular inflammation.
Background Atherosclerosis is driven by sustained recruitment and accumulation of monocytes and macrophages within arterial walls through chemokine-mediated pathways. Netrin-1, an immunomodulatory molecule originally identified in neural development, has emerged as a potential regulator of vascular inflammation, though its precise effects on chemokine-driven leukocyte migration remain undefined. Methods We investigated netrin-1 effects on macrophage migration in vitro using real-time impedance-based assays and assessed systemic effects in vivo through intravital microscopy and aortic sinus histology in an inflammation-induced model. Results Netrin-1 selectively inhibited CCL2-driven macrophage migration in vitro , reducing migration when combined with the chemokine compared to chemokine alone. In an acute inflammation mouse model, systemic netrin-1 pre-treatment showed a trend toward the decrease of monocyte adhesion and transmigration into the tissue while increasing rolling interactions, suggesting impaired firm adhesion and diapedesis. Importantly, hyperlipidaemic LDLR − / − mice presented enlarged aortic sinus after being fed a high-fat diet, and this enlargement was not observed when netrin-1 was continuously administered via osmotic minipumps. Conclusions Our data suggests that systemic netrin-1 selectively inhibits chemokine-driven monocyte migration in vitro , with potential implications for reducing vascular inflammatory cell recruitment, an important component of atherogenesis.
No takes yet. Share an insight, caveat, or question.
Claro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: